Impact of restricting access to high-cost medications for hepatocellular carcinoma

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 4, 2012, Pages 465-473

  Ma, Yuk Ting ^a   Palmer, Daniel H ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

cost effectiveness; hepatocellular carcinoma; sorafenib

Indexed keywords

AXITINIB; BRIVANIB; CEDIRANIB; CISPLATIN; DOVITINIB; DOXORUBICIN; ERLOTINIB; LINIFANIB; NINTEDANIB; ORANTINIB; PAZOPANIB; PLACEBO; REGORAFENIB; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMBINATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COMPETITION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; HEALTH CARE ACCESS; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER DYSFUNCTION; LIVER RESECTION; MONOTHERAPY; NONHUMAN; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMIC THERAPY; TUMOR ABLATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIVER NEOPLASMS; PYRIDINES;

EID: 84866671482     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.33     Document Type: Review

References (45)

1. National Collaborating Centre for Chronic Conditions. Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. Royal College of Physicians, London, UK (2009
2. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. Royal College of Physicians, London, UK (2008
3. Lawrence RC, Felson DT, Helmick CG et al.; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58(1), 26-35 (2008
4. Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41(5), 778-799 (1998
5. Altman RD. Early management of osteoarthritis. Am. J. Manag. Care 16(Suppl. Management), S41-S47 (2010
6. Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin. Rheumatol. 30(Suppl. 1), S3-S8 (2011
7. White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in aninsured population in the United States. J. Occup. Environ. Med. 50(9), 998-1005 (2008
8. Sarzi-Puttini P, Cimmino MA, Scarpa R et al. Osteoarthritis: An overview of the disease and its treatment strategies. Semin. Arthritis Rheum. 35(Suppl. 1), 1-10 (2005
9. Schnitzer TJ, Hochberg MC. COX-2-selective inhibitors in the treatment of arthritis. Cleve. Clin. J. Med. 69(Suppl. 1), SI20-SI30 (2002
10. White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials. Am. J. Cardiol. 99(1), 91-98 (2007
11. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet 376(9736), 173-179 (2010
12. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res. Ther. 7(3), R644-R665 (2005
13. Silverstein FE, aich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and heumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10), 1247- 255 (2000
14. Chung SJ, Kwon YJ, Park HJ, Ko SK, Park MC. Cost-effectiveness of celecoxib, nonselective NSAID and NSAID with proton-pump inhibitor in patients with rheumatoid rthritis in Korea. Ann. Rheum. Dis. 69(Suppl. 3), 684 (2010
15. Contreras-Hernández I, Mould-Quevedo JF, Torres-González R et al. Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost Eff. Resour. Alloc. 6, 21 (2008
16. Lee KK, You JH, Ho JT et al. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. Aliment. Pharmacol. Ther. 18(2), 217-222 (2003
17. Yen ZS, Lai MS, Wang CT et al. Costeffectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J. Rheumatol. 31(9), 1797-1803 (2004
18. Yilmaz H, Gurel S, Keskinaslan A, Ozdemir O. The comparison of alternatives in osteoarthritis treatment with costminimization analysis. Turkiye Fiziksel. Tip. Ve. Rehabilitasyon Dergisi. 50(2), 4-10 (2004
19. You JH, Lee KK, Chan TY, Lau WH, Chan FK. Arthritis treatment in Hong Kong - cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Aliment. Pharmacol. Ther. 16(12), 2089-2096 (2002
20. El-Serag HB, Graham DY, Richardson P, Inadomi JM. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: The use of a nomogram in cost-effectiveness analysis. Arch. Intern. Med. 162(18), 2105-2110 (2002
21. Kamath CC, Kremers HM, Vanness DJ, O'Fallon WM, Cabanela RL, Gabriel SE. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 6(2), 144-157 (2003
22. Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol. 7, 25 (2007
23. Schaefer M, DeLattre M, Gao X, Stephens J, Botteman M, Morreale A. Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Curr. Med. Res. Opin. 21(1), 47-60 (2005
24. Maetzel A. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment 6, 1-15 (2002
25. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum. 49(3), 283-292 (2003
26. Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. J. Med. Econ. 12(3), 246-258 (2009
27. Zabinski R, Burke T, Johnson J et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 19(Suppl. 1), 49-58 (2001
28. Moreno A, Vargas E, Soto J, Rejas J. Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis. Gac. Sanit. 17(1), 27-36 (2003
29. Rubio-Terres C, Moller PI, Campeny ET, Verges MJ. Pharmacoeconomic analysis of arthrosis treatment with chondroitin sulfate in comparison to NSAIs. Atencion Farmaceutica 6(1), 15-27 (2004
30. Vargas E, Laredo L, Soto J, Rejas J. Economic evaluation of celecoxib in the treatment of arthrosis. Atencion Farmaceutica 4(2), 72-82 (2002
31. Chen YF, Jobanputra P, Barton P et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation. Health Technol. Assess. 12(11), 1-278, iii (2008
32. Holmstrom S, Svedbom A, Borgstrom F, Miltenburger C. Estimation of costs related to adverse events in NSAID treatment of osteoarthritis - a comparison between celecoxib and ibuprofen using a validated model. Presented at: International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting. Orlando, FL, USA, 16-20 May 2009.
33. Lucioni C, Chiroli S, Roggeri D, Annoni G. Cost-analysis of a 6-week cycle of therapy with celecoxib vs conventional NSAIDs in ostheoarthritis in Italy. PharmacoEcon. Ital. Res. Art. 5(1), 23-34 (2003
34. Dahlberg LE, Holme I, Høye K, Ringertz B. A randomized, multicentre, doubleblind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand. J. Rheumatol. 38(2), 133-143 (2009
35. Chancellor JV, Hunsche E, de Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 19(Suppl. 1), 59-75 (2001
36. Al MJ, Maniadakis N, Grijseels EW, Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands. Value Health 11(4), 589-599 (2008
37. Inotai A, Mészáros A. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. Int. J. Technol. Assess. Health Care 25(2), 190-195 (2009
38. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal antiinflammatory drugs in the general population. J. Am. Coll. Cardiol. 52(20), 1628-1636 (2008
39. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011
40. Soloman N. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005
41. Arber N, Eagle CJ, Spicak J et al.; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355(9), 885-895 (2006
42. Bombardier C. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 21, 1520-1528 (2000
43. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. Am. J. Manag. Care 13(6 Pt 2), 370-376 (2007
44. Moride Y, Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology (Oxford) 42(Suppl. 3), iii17-iii22 (2003
45. Shi W, Wang YM, Li LS et al. Safety and efficacy of oral nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis: A six-month randomised study. Clin. Drug Investig. 24(2), 89-101 (2004